Bayside Biosciences

Bayside BioSciences is a privately held, revenue-generating contract research organization (CRO) specializing in preclinical drug development services. Founded in 2010, the company leverages its team's deep industry experience in oncology and immunology to provide flexible, one-stop preclinical solutions for biotech and pharma clients. Its core value proposition is accelerating client timelines through rapid study initiation and adaptive study designs, though it does not appear to develop its own proprietary drug pipeline.

Integrated preclinical contract research services including assay development, bioanalysis, molecular/cell biology, and in vitro/in vivo pharmacology for multiple therapeutic modalities (antibodies, small molecules, siRNA, proteins, gene therapy).

Operates in the highly competitive preclinical CRO market, competing against large public players (e.g., LabCorp, IQVIA) and numerous niche providers. Differentiation is based on scientific expertise in complex modalities, flexibility, and personalized service, rather than scale.